Plaque-type Psoriasis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01936688 -
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
|
Phase 3 | |
Completed |
NCT00763503 -
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
|
Phase 2 | |
Completed |
NCT00773734 -
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
|
Phase 2 | |
Completed |
NCT01258088 -
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
|
Phase 1 | |
Completed |
NCT01132612 -
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT00852761 -
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
|
Phase 4 | |
Completed |
NCT00625326 -
Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
|
Phase 2 | |
Completed |
NCT01412944 -
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
|
Phase 3 | |
Completed |
NCT00521339 -
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT01876875 -
n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis
|
Phase 4 |